Molecular epidemiology of malaria in Yaounde, Cameroon IV. Evolution of pyrimethamine resistance between 1994 and 1998

American Journal of Tropical Medicine and Hygiene

Volumn 61, Issue 5, 1999, Pages 802-806

  Basco, Leonardo K ^a,b   Ringwald, Pascal ^a,b  

^a Laboratoire de Recherche sur le Paludisme Yaounde   (Cameroon)

^b Institut de Recherche pour le Developpement Cameroon   (Cameroon)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; DNA; PYRIMETHAMINE; SULFADOXINE;

ARTICLE; CAMEROON; DNA SEQUENCE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALARIA; NONHUMAN; PLASMODIUM FALCIPARUM; POINT MUTATION; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

PLASMODIUM FALCIPARUM; PROTOZOA;

EID: 0032735045     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.1999.61.802     Document Type: Article

References (42)

1. Watkins WM, Mberu EK, Winstanley PA, Plowe CV, 1997. The efficacy of antifolate antimalarial combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses. Parasitol Today 13: 459-464.
2. Falco EA, Goodwin LG, Hitchings GH, Rollo IM, Russell PB, 1951. 2,4-diaminopyrimidines - a new series of antimalarials. Br J Pharmacol 6: 185-200.
3. Peters W, 1987. Chemotherapy and Drug Resistance in Malaria. Second edition. London: Academic Press.
4. Wernsdorfer WH, Payne D, 1991. The dynamics of drug resistance in Plasmodium falciparum. Pharmacol Ther 50: 95-121.
5. Phillips-Howard PA, Björkman AB, 1990. Ascertainment of risk of serious adverse reactions associated with chemoprophylactic antimalarial drugs. Bull World Health Organ 68: 493-504.
6. World Health Organization, 1990. Practical chemotherapy of malaria. World Health Organ Tech Rep Ser 805.
7. Hyde JE, 1990. The dihydrofolate reductase-thymidylate synthetase gene in the drug resistance of malaria parasites. Pharmacol Ther 48: 45-59.
8. Foote SJ, Cowman AF, 1994. The mode of action and the mechanism of resistance to antimalarial drugs. Acta Trop 56: 157-171.
9. Ferone R, Burchall JJ, Hitchings GH, 1969. Plasmodium berghei dihydrofolate reductase: isolation, properties, and inhibition by antifolates. Mol Pharmacol 5: 49-59.
10. Ferone R, 1984. Dihydrofolate reductase inhibitors. Peters W, Richards WHG, eds. Antimalarial Drugs II. Current Antimalarials and New Drug Developments. Berlin: Springer-Verlag, 207-221.
11. Bzik DJ, Li WB, Horii T, Inselburg J, 1987. Molecular cloning and sequence analysis of the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene. Proc Natl Acad Sci USA 84: 8360-8364.
12. Snewin VA, England SM, Sims PFG, Hyde JE, 1989. Characterization of the dihydrofolate reductase-thymidylate synthetase gene from human malaria parasites highly resistant to pyrimethamine. Gene 76: 41-52.
13. Cowman AF, Morry MJ, Biggs BA, Cross GA, Foote SJ, 1988. Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proc Natl Acad Sci USA 85: 9109-9113.
14. Peterson DS, Walliker D, Wellems TE, 1988. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci USA 85: 9114-9118.
15. Zolg JW, Plitt JR, Chen GX, Palmer S, 1989. Point mutations in the dihydrofolate reductase-thymidylate synthase gene as the molecular basis for pyrimethamine resistance in Plasmodium falciparum. Mol Biochem Parasitol 36: 253-262.
16. Basco LK, Ringwald P, 1998. Molecular epidemiology of malaria in Yaounde, Cameroon. I. Analysis of point mutations in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Am J Trop Med Hyg 58: 369-373.
17. Ringwald P, Bickii J, Basco L, 1996. Randomised trial of pyronaridine versus chloroquine for acute uncomplicated falciparum malaria in Africa. Lancet 347: 24-28.
18. Ringwald P, Bickii J, Basco LK, 1998. Efficacy of oral pyronaridine for the treatment of acute uncomplicated falciparum malaria in African children. Clin Infect Dis 26: 946-953.
19. Mount DL, Nahlen BL, Patchen LC, Churchill FC, 1989. Adaptations of the Saker-Solomons test: simple, reliable colorimetric field assays for chloroquine and its metabolites in urine. Bull World Health Organ 67: 295-300.
20. Warrell DA, Molyneux ME, Beales PF, 1990, Severe and complicated malaria. Trans R Soc Trop Med Hyg 84: 1-65.
21. Trager W, Jensen JB, 1976. Human malaria parasites in continuous culture. Science 193: 673-675.
22. Basco LK, Eldin de Pécoulas P, Wilson CM, Le Bras J, Mazabraud A, 1995. Point mutations in the dihydrofolate reductase-thymidylate synthase gene and pyrimethamine and cycloguanil resistance in Plasmodium falciparum. Mol Biochem Parasitol 69: 135-138.
23. Parzy D, Doerig C, Pradines B, Rico A, Fusai T, Doury JC, 1997. Proguanil resistance in Plasmodium falciparum African isolates: assessment by mutation-specific polymerase chain reaction and in vitro susceptibility testing. Am J Trop Med Hyg 57: 646-650.
24. Wang P, Lee CS, Bayoumi R, Djimde A, Doumbo O, Swedberg G, Dao LD, Mshinda H, Tanner M, Watkins WM, Sims PFG, Hyde JE, 1997. Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins. Mol Biochem Parasitol 89: 161-177.
25. Nzila-Mounda A, Mberu EK, Sibley CH, Plowe CV, Winstanley PA, Watkins WM, 1998. Kenyan Plasmodium falciparum field isolates: correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain. Antimicrob Agents Chemother 42: 164-169.
26. Eldin de Pécoulas P, Basco LK, Abdallah B, Djé MK, Le Bras J, Mazabraud A, 1995. Plasmodium falciparum: detection of antifolate resistance by mutation-specific restriction enzyme digestion. Exp Parasitol 80: 483-487.
27. Eldin de Pécoulas P, Basco LK, Le Bras J, Mazabraud A, 1996. Association between antifol resistance in vitro and DHFR point mutation in Plasmodium falciparum isolates. Trans R Soc Trop Med Hyg 90: 181-182.
28. Foote SJ, Galatas D, Cowman AF, 1990. Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc Natl Acad Sci USA 87: 3014-3017.
29. Peterson DS, Milhous WK, Wellems TE, 1990. Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proc Natl Acad Sci USA 87: 3018-3022.
30. Desjardins RE, Canfield CJ, Haynes JD, Chulay JD, 1979. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother 16: 710-718.
31. Basco LK, Ramiliarisoa O, Le Bras J, 1994. In vitro activity of pyrimethamine, cycloguanil, and other antimalarial drugs against African isolates and clones of Plasmodium falciparum. Am J Trop Med Hyg 50: 193-199.
32. Ringwald P, Bickii J, Basco LK, 1996. In vitro activity of antimalarials against clinical isolates of Plasmodium falciparum in Yaounde, Cameroon. Am J Trop Med Hyg 55: 254-258.
33. Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE, 1995. Pyrimethamine and proguanil resistance-conferring in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg 52: 565-568.
34. Plowe CV, Cortese JF, Djimde A, Nwanyanwu OC, Watkins WM, Winstanley PA, Estrada-Franco JG, Mollinedo RE, Avila JC, Cespedes JL, Carter D, Doumbo OK, 1997. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis 176: 1590-1596.
35. Reeder JC, Rieckmann KH, Genton B, Lorry K, Wines B, Cowman AF, 1996. Point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes and in vitro susceptibility to pyrimethamine and cycloguanil of Plasmodium falciparum isolates from Papua New Guinea. Am J Trop Med Hyg 55: 209-213.
36. van Dijk MR, Waters AP, Janse CJ, 1995. Stable transfection of malaria parasite blood stages. Science 268: 1358-1362.
37. Wu Y, Kirkman LA, Wellems TE, 1996. Transformation of Plasmodium falciparum malaria parasites by homologous integration of plasmids that confer resistance to pyrimethamine. Proc Natl Acad Sci USA 93: 1130-1134.
38. Sirawaraporn W, Sathitkul T, Sirawaraporn R, Yuthavong Y, Santi DV, 1997. Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proc Natl Acad Sci USA 94: 1124-1129.
39. Sirawaraporn W, Yongkiettrakul S. Sirawaraporn R, Yuthavong Y, Santi DV, 1997. Plasmodium falciparum: asparagine mutant at residue 108 of dihydrofolate reductase is an optimal antifolate-resistant single mutant. Exp Parasitol 87: 245-252.
40. Cortese JF, Plowe CV, 1998. Antifolate resistance due to new and known Plasmodium falciparum dihydrofolate reductase mutations expressed in yeast. Mol Biochem Parasitol 94: 205-214.
41. Curtis J, Duraisingh MT, Trigg JK, Mbwana H, Warhurst DC, Curtis CF, 1996. Direct evidence that asparagine at position 108 of the Plasmodium falciparum dihydrofolate reductase is involved in resistance to antifolate drugs in Tanzania. Trans R Soc Trop Med Hyg 90: 678-680.
42. Zindrou S, Le DD, Pham TX, Nguyen PD, Nguyen DS, Skold O, Swedberg G, 1996. Rapid detection of pyrimethamine susceptibility of Plasmodium falciparum by restriction endonuclease digestion of the dihydrofolate reductase gene. Am I Trop Med Hyg 54: 185-188.